Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMACare phase II study of lutetium (177Lu) vipivotide tetraxetan with or without androgen receptor pathway inhibitor in PSMA PET-positive castration-resistant prostate cancer
CTR20240678Phase 2Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- Feb 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Advanced Accelerator Applications. Started Feb 2024; status: terminated.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20240678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240678.